Skip to main content
letter
. 2015 May;100(5):e190–e193. doi: 10.3324/haematol.2014.115337

Figure 2.

Figure 2.

DOT1L inhibition abrogates H3K79me2 and leads to downregulation of MLL targets in MLL-PTD leukemia cell lines. (A) H3K79me2 profile of the HOXA-locus in the MLL-PTD positive EOL-1 cell line as assessed by ChIP-seq. (B) Western blot analysis of global H3K79me2 levels in KOPM-88, EOL-1, MOLM-13 and HL-60 human leukemia cell lines following four days of treatment with EPZ004777. (C) Heatmap of the top 100 down-regulated genes in biological triplicates of EOL-1 cells following 10 μM EPZ004777 treatment (right) for seven days as compared to DMSO vehicle control (left). (D) GSEA of genes down-regulated by 10 μM EPZ004777 treatment of EOL-1 cells for seven days as compared with genes bound by MLL-AF9 in MLL-AF9 transformed murine hematopoietic progenitors. The heatmap indicates differential expression of MLL-AF9 fusion genes between EOL-1 cells treated with either DMSO vehicle control (DMSO, left) or 10 μM EPZ004777 (EPZ, right).